Table 4

Drug-Related Adverse Events Reported by ≥ 15% of Patients Who Received Vorinostat Combination Therapy in the Vorinostat Clinical Trial Program (Data Cut-Off April 2008)

Adverse Event

No. (%) of Patients (N = 157)

All Grades

Grade 3 or 4

Nausea

76 (48.4)

8 (5.1)

Diarrhea

64 (40.8)

9 (5.7)

Fatigue

54 (34.4)

21 (13.4)

Vomiting

49 (31.2)

6 (3.8)

Anorexia

32 (20.4)

4 (2.5)

Dehydration

28 (17.8)

6 (3.8)

Thrombocytopenia

25 (15.9)

15 (9.6)

Anemia

25 (15.9)

4 (2.5)

Siegel et al. Journal of Hematology & Oncology 2009 2:31   doi:10.1186/1756-8722-2-31